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Abstract  26!
Wide surgical resection or a marginal/incomplete resection followed by full-course radiation 27!
therapy is the current standard of care for canine soft tissue sarcoma. The herein presented 28!
results of a retrospective, cross-sectional, bi-institutional study describe the effectiveness and 29!
toxicity of a hypofractionated 5x6 Gy protocol on macroscopic canine soft tissue sarcoma in 30!
terms of progression-free interval and overall survival, identifying prognostic factors on 31!
outcome.   32!
Dogs with macroscopic soft tissue sarcoma irradiated with 5x6 Gy were eligible for the study. 33!
Progression-free interval and overall survival were compared with respect to different tumor 34!
and patient characteristics by the Kaplan-Meier-method and multivariable Cox-regression 35!
analysis. Fifty dogs with macroscopic disease were included. All dogs received the same 36!
radiation therapy protocol; part of the group (n=20) received post-radiation metronomic 37!
chemotherapy. Median progression-free interval for all cases was 419 days (95%CI:287-551) 38!
and median overall survival was 513 days (95%CI:368-658). Dogs with tumors on the limbs 39!
had significantly longer progression-free interval and overall survival, compared with head or 40!
trunk. Increasing tumor burden decreased overall survival. The addition of metronomic 41!
chemotherapy yielded a significantly longer overall survival (757 days (95%CI:570-944)  42!
compared with dogs that did not receive systemic treatment (286 days (95%CI:0-518), 43!
(p=0.023)), but did not influence progression-free interval. Toxicity was low throughout all 44!
treatments. The 5x6 Gy radiation therapy protocol was well tolerated and provided long 45!
progression-free interval and overall survival in dogs with macroscopic soft tissue sarcoma.  46!
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Introduction  47!
Soft tissue sarcomas refer to a group of malignant tumors that arise from mesenchymal cells 48!
and can occur in any part of the body, most commonly in the extremities and trunk. Although 49!
canine soft tissue sarcomas present with wide variations in subtypes (fibrosarcoma, 50!
perivascular wall tumors, peripheral nerve sheet tumors, liposarcoma, myxosarcoma, 51!
malignant mesenchymoma)1, 2, these tumors tend to have a similar biologic behavior, 52!
consisting of locally invasive growth and usually a low-to-intermediate metastatic potential. 53!
Conversely, other mesenchymal tumors also arising from soft tissues, including 54!
hemangiosarcoma, histiocytic sarcoma and rhabdomyosarcoma, have a more aggressive 55!
biologic behavior and a higher tendency to spread.3 Surgery with or without full-course post-56!
operative radiation therapy is the mainstay of treatment of canine soft tissue sarcomas.2, 4-6 57!
Adequate treatment yields long survival times ranging from 14163 to 2270 days4, 5, with only 58!
33% of the cases succumbing to the disease. However, analyses of prognostic factors showed 59!
that the extent of resection, initial tumor size, anatomical location, histological grade and 60!
clinical stage were predictive of outcome.3-5 It is well documented that the extent of resection 61!
is associated with local control of soft tissue sarcoma.6, 7 However, one study describes that 62!
some of these tumors resected without an adequate margin of normal tissue may only have a 63!
failure rate of about 30%.8 Unfortunately, in some clinical situations, surgery cannot be used 64!
without unacceptable morbidity, or gross disease is left behind at resection in an attempt to 65!
spare critical normal structures or avoid amputation in the case of soft tissue sarcoma located 66!
on the extremities.  67!
Hypofractionated radiation therapy protocols for macroscopic or microscopic canine soft 68!
tissue sarcomas are currently used in a true palliative (e.g. providing pain relief and 69!
improvement of dysfunction)9, 10 setting for elderly patients or patients presenting with serious 70!
co-morbidities, but also due to financial restraint of owners or logistical restraint of treatment 71!
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machine availability.11-13 The responses in the macroscopic setting using a 4x8 Gy weekly 72!
protocol have been found to be rather short-lived with about 5 months of median time to 73!
progression.11 Traditional dose-intense chemotherapy as a single treatment modality has not 74!
proven to be effective in local tumor control; nevertheless, the administration of metronomic 75!
chemotherapy has recently shown to delay tumor recurrence after incomplete resection of 76!
canine soft tissue sarcomas14, most likely by inhibiting tumor angiogenesis and suppressing 77!
regulatory T-cells.15 78!
With these considerations in mind, this retrospective, cross-sectional, bi-institutional study 79!
was conducted to assess the effectiveness of a previously published 5x6 Gy hypofractionated 80!
radiation therapy protocol13, 16-19, with or without post-radiation metronomic chemotherapy, in 81!
dogs with macroscopic (including unresected or recurrent) soft tissue sarcoma, and to 82!
evaluate tumor and treatment variables associated with local control and survival. It was 83!
hypothesized that the hypofractionated radiation therapy protocol would result in good 84!
tolerability and provide long progression-free interval and overall survival. 85!
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Materials and Methods  86!
Patient and tumor characteristics 87!
Medical records of dogs with soft tissue sarcomas admitted to the Division of Radiation 88!
Oncology of the Vetsuisse-Faculty, University of Zurich, and the Centro Oncologico 89!
Veterinario, Sasso Marconi, Bologna, between 2006 and 2013 were reviewed. Due to the 90!
retrospective nature of this study, reporters were aware of outcome at the time of data 91!
recording. 92!
Dogs were included in the study if they had a soft tissue sarcoma that was diagnosed by 93!
means of histopathology, underwent a 5x6 Gy radiation therapy protocol in a macroscopic 94!
setting with or without post-radiation metronomic chemotherapy. Dogs were excluded if their 95!
tumor occurred in the oral or nasal cavity, if they had received previous chemotherapy and/or 96!
radiation therapy, or in the case of histopathological diagnosis demonstrating histiocytic 97!
sarcoma, angiosarcoma or rhabdomyosarcoma, due to the documented different biological 98!
behavior.3, 11, 20 Each dog had previously been evaluated through medical history, physical 99!
examination, routine blood tests, thoracic radiographs and other appropriate imaging studies. 100!
Information retrieved from all medical records included: signalment (age, sex, breed), 101!
concurrent diseases, presentation (primary versus recurrent), number of previous surgeries, 102!
involved sites, tumor size, histology, histological grade, clinical stage, treatment modality 103!
(electron versus photon plan), response to radiation therapy, time to disease progression, 104!
treatment-related complications, time and cause of death, and date of last follow-up visit. 105!
Tumor site was classified as head (excluding oral and nasal cavity), trunk, and extremities. 106!
Pathologic diagnoses were made by experienced pathologists (Dipl. ECVP) at the time of 107!
treatment according to currently accepted criteria.21 Histological grade was based on a scale 108!
of 3 (low, intermediate, high grade).3 The size of the tumor before radiation therapy was 109!
evaluated by caliper measurement from physical examination, radiography, and/or computed 110!
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tomography (CT), depending on anatomical site and clinicians’ and/or owners’ preferences. 111!
Tumor volume was calculated by the rotational ellipse method (max. height x max. width x 112!
max. length x π/6). Staging workup for regional and distant disease included fine-needle 113!
aspiration of the regional lymph node, thoracic radiography and abdominal ultrasound, and/or 114!
total body CT, depending on clinicians’ and/or owners’ preferences. Stage was established 115!
with the modified TNM staging system.22 116!
 117!
Treatment 118!
All dogs were treated with external beam megavoltage radiation therapy. Radiation was 119!
delivered with a 6 megavolt (MV) linear accelerator (Dynaray LA20; ABB, Clinac DMX or 120!
Clinac iX, Varian, Palo Alto, USA) using either photons (3-dimensional conformal radiation 121!
therapy, 3DCRT) or electrons, depending on tumor size and location. Treatment planning was 122!
performed on the basis of CT for photon plans or by hand calculation for electron plans. For 123!
treatment planning, the Eclipse External Beam Planning system version 8.1 or 10.0 (Varian 124!
Oncology Systems, Palo Alto, CA) was used, applying the pencil beam convolution- (version 125!
8.6.14) or AAA-algorithm (10.0.28). Dogs were under general anesthesia for planning-CT 126!
and daily treatment, and – if treated with photon plans - immobilized in an individually 127!
shaped vacuum cushion (BlueBag BodyFix, Elekta AB, Stockholm, Sweden). Dogs with 128!
tumors in the head area were additionally immobilized with a custom-made bite block.23 The 129!
GTV (gross tumor volume) was delineated using co-registered or in parallel viewed contrast-130!
enhanced CT images, and CTV (clinical target volume), accounting for subclinical 131!
microscopic disease extension of 2-3 cm (presumed local infiltration) as well as positive 132!
regional lymph nodes), was defined. The CTV-margin was then extended three-dimensionally 133!
by 2 mm (for image-guided photon treatment), or 4-6 mm (for non-guided photon treatment) 134!
! 7!
to define the planning target volume (PTV), accounting for internal physiologic movements, 135!
patient motion, and setup uncertainties. Organs at risk were segmented as applicable.  136!
The recommendations for specifying dose and volumes as proposed for veterinary 137!
medicine were adhered to as proposed in the corresponding literature.24-26 For photon 138!
plans, the prescribed dose was 30 Gy at the ICRU reference point25, delivered in 5 139!
fractions of 6 Gy applied twice per week, resulting in an overall treatment time of 2.5 140!
weeks. Treatment was performed isocentrically with bolus and wedges to ensure dose 141!
homogeneity for photon treatments. For tumors treated with electron fields, the 142!
according fields were applied at 100 cm source surface distance (SSD) and field sizes 143!
as well as energies were chosen to adequately cover the tumor with the additional 144!
suspected margin of infiltration of 2-3 cm. The 90% isodose line was chosen to 145!
encompass this target volume and for dose normalization.27 146!
Radiation-related toxicity was graded according to the Veterinary Radiation Therapy 147!
Oncology Group (VRTOG) scheme at each treatment, and 2-3 weeks after having 148!
completed the protocol, thereafter monthly rechecks were scheduled.28 Specific 149!
attention was paid to wound-healing complications, in-field fractures, vascular 150!
complications, and second malignancies. The recommendation for use of metronomic 151!
chemotherapy was based on the judgment of the clinicians managing the cases and on 152!
owners’ preferences, and consisted of oral administration of thalidomide (Thalidomide 153!
CEG, Celgene srl, Milan, Italy; 1-2 mg/kg/per day), piroxicam (Feldene, Pfizer, Rome, 154!
Italy; 0.3 mg/kg/per day) and cyclophosphamide (Endoxan, Baxter, Rome, Italy; 7 155!
mg/m2/every other day). All drugs were re-formulated and administered to the nearest 156!
5 mg. 157!
 158!
Outcome and follow-up 159!
! 8!
Outcome information was obtained by means of medical records or communication with 160!
referring veterinarians and owners at the end of the study period. Follow-up care included a 161!
medical history and physical examination at progressive intervals beyond treatment. Response 162!
data was noted according to the RECIST criteria for dogs.29 Complete remission was defined 163!
as the disappearance of all target lesions. Partial response (PR) was defined as a reduction of 164!
at least 30% in the sum of diameters of target lesions from baseline. Stable disease (SD) was 165!
defined as < 30% decrease or >20% increase in sum of diameters of target lesions from 166!
smallest sum while on treatment. Progressive disease (PD) was defined as an increase in the 167!
sum of diameters of target lesions by at least 20% over the size present at entry on study, or 168!
the appearance of new lesions. Responses were required to last for at least 28 days. Follow-up 169!
imaging was individualized based on baseline risk, symptoms, and clinicians’ and/or owners’ 170!
preferences, and included thoracic radiographs and abdominal ultrasound or total body CT. 171!
 172!
Statistical analysis 173!
Statistical evaluation was performed together with a biostatistician (M.R.) and computed with 174!
a commercial statistical software package (IBM® SPSS® Statistics, Version 22). Description 175!
of quantitative data characteristics, other than progression-free interval (PFI) and overall 176!
survival (OS), is given by mean (± SD), unless otherwise specified. For qualitative 177!
characteristics absolute and relative frequencies were provided. Association of discrete patient 178!
or tumor specific variables on the addition of adjuvant metronomic chemotherapy was 179!
evaluated with the Chi-square-test or logistic regression. For logistic regression odds ratio 180!
(OR) together with the corresponding 95%CI(OR) were computed. 181!
PFI was defined as the interval between the first fraction of radiation therapy to measurable 182!
progression of disease, while OS was defined as the interval between the first fraction of 183!
radiation therapy and death. Dogs that were still free of progression at the time of data 184!
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evaluation were censored. For OS, all deaths were considered events and dogs that were still 185!
alive at the time of data evaluation or lost to follow-up were censored. The Kaplan-Meier 186!
survival analysis was followed by logrank or Breslow-Gehan-Wilcoxon tests. In case the 187!
survival curves did not cross the logrank test was applied. Otherwise the Breslow-Gehan-188!
Wilcoxon test was used. The multivariable Cox-regression analysis was used to determine 189!
whether the following factors were significantly associated with PFI or OS: presentation 190!
(primary versus recurrent), number of previous surgeries, involved sites (head and neck 191!
versus trunk versus extremities), tumor size, histology, histological grade (1 versus 2 versus 192!
3), regional lymph node metastasis (present versus absent), distant metastasis (present versus 193!
absent), medical treatment (yes versus no). Survival estimates are presented as median with 194!
the corresponding 95% confidence intervals (95%CI).  In case median survival was not 195!
reached, the mean survival with the corresponding 95%CI was reported. For Cox-regression 196!
hazard ratio (HR) together with the corresponding 95%CI(HR) were computed. For factors 197!
not only the global p-value but also the pairwise Bonferroni-corrected post-hoc tests were 198!
reported. A p-value of <0.05 was considered significant for all analyses. For between levels 199!
comparisons of three-level factors within Cox-regression the Bonferroni correction was 200!
applied to significance 0.05/3=0.016 and tendency 0.1/3=0.03 levels to perform the pairwise 201!
Bonferroni-corrected post-hoc tests. 202!
 203!
Results  204!
Patient and tumor characteristics 205!
Fifty dogs fulfilled the inclusion criteria for this study, of which 21 were female (15 spayed) 206!
and 29 were male (9 neutered). The dogs were of various pure (n=36) and mixed breeds 207!
(n=14) and a total of 19 breeds were represented. The ages ranged from 4-16 years with a 208!
mean of 9.8 (± 2.7) years. The weight ranged from 8-52 kg, with a mean of 29.3 (± 10.4) kg.  209!
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Of the 17 (34%) dogs that had previous surgeries, 9 (18%) had one and 8 dogs (16%) 210!
had 2. Pretreatment tumor volumes ranged from 0.06 to 491 cm3, with a mean of 118.3 211!
cm3 (± 125). Six tumors (12%) were located on the head, 5 (10%) on the trunk, and the 212!
remaining 39 (78%) on the limbs. Of the 50 cases, 19 tumors (38%) were 213!
histologically described as perivascular wall tumors (including hemangiopericytoma, 214!
spindle cell sarcoma, myopericytoma), 13 (26%) as peripheral nerve sheet tumors, 8 215!
(16%) as fibrosarcoma, 7 (14%) as undifferentiated/anaplastic sarcoma, 2 (4%) were 216!
myxosarcomas, and 1 (2%) was a liposarcoma. Histological grade was given in 42 217!
cases (84%) with 52% grade 1 (n=26), 26% grade 2 (n=13), and 6% grade 3 tumors 218!
(n=3). For these dogs the modified TNM staging was applied and revealed 40 tumors 219!
to be of stage I, and 2 of stage II. For the remaining 8 cases, the histological samples 220!
were not available and grade could not be retrieved. None of the dogs presented with 221!
either regional or distant metastasis. 222!
 223!
Treatment protocol, side effects 224!
Thirty (60%) dogs were treated with single electron fields with energies ranging from 12-15 225!
MeV, and 20 cases (40%) had a 3D-conformal photon plan. Acute side effects were assessed 226!
in 42 cases and consisted of grade 0 toxicity (33.3%) in 14 dogs, grade 1 toxicity (64.3%) in 227!
27 dogs (erythema, dry desquamation, alopecia or epilation) and grade 2 toxicity (2.3%) in 228!
one dog (patchy, moist desquamation, without edema). Late effects were assessed in 37 cases 229!
with no toxicity (67.6%) in 25 dogs, and grade 1 toxicity (32.4%) in 12 dogs (leukotrichia). 230!
Twenty dogs received additional metronomic chemotherapy. Neither the histological 231!
grouping (p=0.067) nor tumor location (p=0.245) nor volume (p=0.232) was significantly 232!
relevant for the adjunction of chemotherapy. However, the proportion of dogs receiving 233!
metronomic chemotherapy decreased with increasing age. Elderly dogs received metronomic 234!
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chemotherapy less often (OR: 0.713 (95%CI:0.551-0.923), p=0.01) than younger dogs, with a 235!
29% of administration reduction for each additional year of age.  236!
 237!
Response to treatment 238!
Follow-up time for censored cases (n=17) was 561 days (95%CI:482-640, range 87-929 239!
days). Of the 33 animals that were known to have died, 15 (45.5%) died of tumor-related 240!
causes and 18 (54.5%) died of tumor -unrelated causes. At the end of radiation therapy, all 241!
(100%) dogs were evaluated for response. There were 5 (10%) complete responses, 10 (20%) 242!
partial responses, and 35 (70%) stable diseases. At 3-month re-evaluation, 41 (92%) dogs 243!
were assessed for response, and there were 6 complete responses, 13 partial responses, 20 244!
stable diseases, and 2 progressive diseases. At 6-mont re-evaluation, 32 (64%) dogs were 245!
assessed for response, and there were 8 complete responses, 7 partial responses, 13 stable 246!
diseases, and 4 progressive diseases. Median progression free interval for all cases was 419 247!
days (95%CI:287-551). Tumor location significantly influenced PFI, with tumors on the 248!
limbs (median PFI: 466 days (95%CI:321-611)) faring significantly better than tumors on the 249!
head or on the trunk (median PFI: 110 days (95%CI:0-238) and 203 days (mean, median not 250!
reached (SE=31 days (95%CI:142-264), respectively) (p=0.021); ); (head vs. trunk (p=0.421, 251!
ns), head vs. limb (p=0.004, significant), trunk vs. limb (p=0.409, ns) after Bonferroni 252!
correction) (Figure 1).  253!
The number of previous surgeries also significantly influenced PFI. Dogs having had >1 prior 254!
surgery had the shortest PFI (105 days (95%CI:0-349)), whereas dogs with no prior surgery 255!
or with one prior surgery were free of progression for a median of 420 days  (95%CI:285-256!
556) and 536 days (95%CI:92-980) (p=0.003); (no surgery vs. one surgery (p=0.579, ns), no 257!
surgery vs. > 1 surgeries (p=0.02, tendency), one surgery vs. > 1 surgeries (p=0.027, 258!
tendency)), respectively. Histology (p=0.080), tumor grade (p=0.167), radiation therapy 259!
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modality (p=0.585), age (p=0.296), and pretreatment volume (p=0.658) did not significantly 260!
influence PFI. 261!
Median overall survival was 513 days (95%CI:368-658). Regarding histology, a significantly 262!
shorter survival in the fibrosarcoma group versus all other histologies was found (median 190 263!
days (95%CI:38-343)) (p<0.001); grade did not influence survival (p=0.922). However, 264!
location was documented to be a significant prognostic factor: dogs with tumors on the limbs 265!
survived longer (579 days (95% CI:452-706) than those with tumors on the head (195 days 266!
(95%CI: 51-339)) and on the trunk (190 days (95%CI: 57-323)), (p=0.031); (head vs. trunk 267!
(p=0.366, ns), head vs. limb (p=0.038, ns), trunk vs. limb (p=0.015, significant) after 268!
Bonferroni correction) (Figure 2). 269!
No association was found for tumor grade (p=0.631), treatment modality (p=0.735), or age 270!
(p=0.412), however, increasing tumor volume decreased OS (HR 1.004 (95%CI:1.001-1.007), 271!
p=0.005). The number of previous surgeries showed no significant association with OS.  272!
The addition of metronomic chemotherapy did not influence the duration of PFI, however, 273!
dogs receiving metronomic chemotherapy had a significantly longer OS (757 days 274!
(95%CI:570-944) compared with dogs that did not receive systemic treatment (286 days 275!
(95%CI:0-518), (p=0.023)) (Figure 3). Interestingly, 3 dogs receiving metronomic 276!
chemotherapy that achieved partial response (n=2) or stable disease (n=1) at the end of 277!
radiation therapy obtained complete response at 6-month re-evaluation, and 1 dog that had 278!
stable disease at the end of radiation therapy obtained partial response at 6-month re-279!
evaluation.  280!
! 13!
Discussion  281!
The present study is based on a large number of dogs with soft tissue sarcoma with 282!
macroscopic (unresected or recurrent) disease treated with a hypofractionated 5x6 Gy 283!
radiation therapy protocol. For several reasons, such as financial or logistical restraints of the 284!
owners, co-morbidities of the patients amongst others, there seems to be a demand for non-285!
curative approach for the treatment of canine soft tissue sarcoma. In a previous study, a 4x8 286!
Gy palliative protocol for macroscopic disease revealed short progression free interval of 5.2 287!
months and overall survival of 10.3 months.11 The progression free interval and overall 288!
survival from the current study population were higher, with progression free interval of 13.9 289!
months and overall survival of 17.1 months. Limb tumors fared significantly better with 290!
progression free interval of 15.5 months regardless of tumor burden, histology or grade. The 291!
general finding of long progression free interval and overall survival was surprising, as a 292!
satisfactory outcome of radiation therapy alone for soft tissue sarcoma is not usually expected, 293!
due to the rather low radioresponsiveness of sarcomas. Also, although the great majority of 294!
dogs obtained stable disease at the end of radiation therapy, 10% and 20% of the treated cases 295!
obtained complete responses and partial responses, respectively. Interestingly, the response 296!
rate further improved over time, highlighting that neoplastic cells keep dying off for months 297!
after the end of radiation treatment or respond slowly to metronomic chemotherapy.  298!
The commonly used term “canine soft tissue sarcoma” is used for tumors with similar 299!
biologic behavior.2, 30 However, while not described for surgical or multimodal curative 300!
approach3-5, tumors on the limbs might respond better to hypofractionated protocols12, or the 301!
limb location displays simply less discomfort for the patient.11 Furthermore, this result may be 302!
attributable to the fact that the majority of limb soft tissue sarcomas are histologically 303!
described as perivascular wall tumors.1 Compared to anaplastic sarcomas, it is known that 304!
they usually have less expansile growth with less tissue infiltration, low to no local aggressive 305!
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behavior with recurrence developing after a long latency, and low tendency to metastasize.1, 31  306!
 307!
Management of recurrent tumors is often more difficult, and this study showed that more than 308!
one previous surgery in dogs presenting with macroscopic disease drastically reduced 309!
progression free interval to 3.4 months, while overall survival was not influenced. Multiple 310!
excisions may disrupt or contaminate the tissue planes, cause damage to existing vasculature 311!
with possible subsequent tissue hypoxia and could hypothetically lead to a selection pressure 312!
of cells with a higher malignancy in the recurrent tumor. Furthermore, recurrence of 313!
incompletely excised soft tissue sarcomas has been linked to histological grade 32, with a low 314!
recurrence rate to be expected in a microscopic disease setting of mostly low-grade soft tissue 315!
sarcomas.12 The results of the current study also support this finding. 316!
Larger tumor size is in general considered a poor predictive factor2, 6, however, while most 317!
likely influencing the probability for complete surgical excision, size itself has not been 318!
identified as a prognostic factor in various studies.30, 32, 33 In this study, increasing tumor 319!
volume decreased overall survival, perhaps indicating that larger tumors cause greater 320!
discomfort and prompt owners into the decision of euthanasia earlier. 321!
 322!
Metronomic chemotherapy refers to the frequent administration of cytotoxic drugs at doses 323!
significantly less than the maximum tolerated dose, with no prolonged drug-free breaks, 324!
leading to an anti-angiogenic effect and immune-modulation.34 Unlike traditional 325!
chemotherapy, the main targets of which are proliferating tumor cells, the main targets of 326!
metronomic chemotherapy are the endothelial cells of the growing vasculature of a tumor.34 327!
Although the use of dose-intense chemotherapy has been controversial in dogs with soft tissue 328!
sarcomas, the addition of metronomic chemotherapy has been recently described in the 329!
microscopic setting, leading to significantly prolonged disease-free intervals compared to a 330!
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nonrandomized control group.14 In the current study, dogs receiving metronomic 331!
chemotherapy had a significant improvement in overall survival, whereas the progression free 332!
interval was not increased. Although encouraging, this finding needs to be interpreted 333!
cautiously. First, it should be borne in mind that OS may not be the best endpoint in 334!
veterinary oncology, as it may be influenced by tumor-unrelated factors, such as owners’ 335!
financial concern or logistic issues, leading to premature euthanasia. Second, dogs receiving 336!
metronomic chemotherapy were younger than those that only received radiation therapy, and 337!
it may be possible that owners of younger dogs were more motivated in treating their animals 338!
than owners of elderly patients, which may have elected euthanasia sooner. Several reasons 339!
may explain why elderly dogs are less likely to receive chemotherapy, including the presence 340!
of concomitant diseases and the owner’ unwillingness to accept possible negative effects of 341!
systemic treatment.  342!
Interestingly, some dogs receiving metronomic chemotherapy experienced an improved 343!
response rate over time, with 3 cases obtaining complete response after partial response (n=2) 344!
or stable disease (n=1), and 1 case obtaining partial response after having achieved stable 345!
disease at the end of radiation therapy. Whether the addition of metronomic chemotherapy 346!
after radiation therapy is superior to radiation therapy alone needs to be tested in prospective 347!
trials. With this premise in mind, this study indicates that metronomic chemotherapy warrants 348!
further prospective investigation in canine soft tissue sarcoma to answer several questions. 349!
Indeed, the results obtained here did not allow identifying a subgroup of dogs that are more 350!
likely to benefit from metronomic chemotherapy.  351!
 352!
Acute toxicity of the radiation protocol (mostly grade 0-1 skin reactions) was completely 353!
healed within two to three weeks after completion of treatment. During the time of follow-up, 354!
there was no evidence of late effects, which – due to the lower total dose and smaller fraction 355!
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size - are also expected to a lower degree than in the prior described 4x8 to 9 Gy protocols.11, 356!
12 Compared to Lawrence et al, where the „biologic equivalent dose“ (BED)35 was calculated 357!
to be 117.3 Gy3  (for late effects)11 the comparable BED in this study is lower with 90 Gy3.  358!
For the future, it could be considered to increase the dose per fraction of this protocol slightly, 359!
in order to improve response rate with a likely acceptable complication rate. 360!
Also, toxicity of metronomic chemotherapy was mild as appropriate for a palliative approach, 361!
and allowed outpatient treatment. These findings are in accordance with previous studies.11, 12, 362!
14  363!
 364!
Due to the retrospective nature of this study, the use of archival data, and considering the 365!
well-known difficulty of proper clinical assessment of response of soft tissue sarcoma to 366!
radiation therapy, the authors may not have been able to describe the full range of 367!
improvement in these dogs and some of the information had to be gathered by telephone 368!
follow-up, possibly skewing the information by owner’s perception. Furthermore, different 369!
pathologists made the diagnoses and histological grade was only available in 84% of the 370!
cases. The modified stage grouping could only be applied in patients with known grade.22 As 371!
most of the patients were of stage I disease and the prognostic significance of the staging 372!
system for soft tissue sarcoma has not been further investigated2, the TNM was excluded from 373!
statistical description. The bi-institutionality of the study is of minor concern, as the treatment 374!
planning was either done remotely (all photon plans) or under the direct supervision (electron 375!
hand calculations) by the same radiation oncologist (CRB). 376!
  377!
The standard of care for soft tissue sarcoma remains aggressive local therapy, which often 378!
involves a combination of surgery and full-course post-operative radiation therapy. With this 379!
treatment, median times to recurrence have been described with 700 to 798 days4, 5 and were 380!
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hence considerably longer than the progression free interval of 419 days obtained with the 381!
much more simple protocol described herein. However, for dogs with non-resectable tumors, 382!
the herein described hypofractionated 5x6 Gy protocol is well tolerated and yields a 383!
satisfactory clinical outcome with negligible toxicity found in the clinically relevant observed 384!
time-frame. As with all hypofractionated protocols, a small risk of additional late toxicity 385!
with longer observation remains. Future prospective studies are warranted to determine 386!
whether metronomic chemotherapy after radiation therapy is beneficial for dogs with 387!
macroscopic soft tissue sarcoma.  388!
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Figure captions 483!
Figure 1: Progression-free interval for all cases grouped by tumor location (dotted line: limbs, 484!
solid line: trunk, dashed line: head). 485!
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Figure 2: Overall survival times for all cases grouped by tumor location (dotted line: limbs, 486!
solid line: trunk, dashed line: head). 487!
Figure 3: Overall survival times for patients treated without (dashed line) or with (solid line) 488!
metronomic chemotherapy. 489!



